Life Sciences Archive » February, 2011

Life Sciences - February, 2011

176 articles

• Calif. High Court Revives Baycol Class Action
• Merck-Sanofi Animal Health Joint Venture Delayed
• 5th Circ. Vacates FDA Win On Compounded Drug Review
• Medicis, Teva Resolve Solodyn Patent Suit
• Fed. Circ. Won't Rehear Merck Temodar Patent Case
• Elan, Abbott End Ranbaxy Suit Over Generic TriCor
• Ex-Directors Of Body Armor Co. On Hook For Fraud: SEC
• Fujifilm To Buy 2 Merck Biotech Units For $490M
• French United Worker Can Sue In US: 7th Circ.
• Femina Hits Merck, Pharmacies With NuvaRing 337 Suit
• Colgate Sued Over Toothbrush Packages
• J&J Can't Shake Omnicare FCA Claims
• PDL Settles Novartis IP Row With Lucentis Payments
• A Return To The Wild West For Calif. UCL Actions
• Cephalon, Cima Sue Mylan To Block Generic Fentora
• It's A Raid! Now What?
• High Court Leaves FLSA Status Of Drug Reps Up In Air
• US Wins Fight Over $15M Drug Testing Contract
• Lilly To Pay Up To Resolve Air Emissions Suit
• Mylan Claims Fall In IP Suit Over Generic Azilect
• Bayer Sues Hexal, Salutas Over Heartburn Pill Patents
• Elan Hid Problem With $1B J&J Deal, Investors Say
• Caraco Denied Quick Win On Prandin IP Misuse Claim
• WilmerHale Scores Munger Tolles Patent Pro
• Sandoz Hit With Patent Suit Over Skin Condition Drug
• Securities Litigation Developments In 2010
• Celgene Strikes $78M Deal In Elan Abraxane IP Suit
• FDA Grants Avastin Safety Hearing For Genentech
• Fed. Circ. Reverses Radiation Therapy Patent Ruling
• Former Employee Accuses J&J Of Drug Price Fraud
• Lieff Cabraser Demands Arbitration With Partner
• Mylan Faces Patent Suits Over Generic Estradiol
• Beckman Investor Sues To Block $6.8B Danaher Deal
• Genetic Research Co. Loses Patent License Appeal
• FDA Outlines Initiatives Inspired By DES 'Tragedy'
• Researcher Sues CVS For Prescription Data
• Endo Can't Shake Claims In Roche Generic Valcyte Suit
• WilmerHale Reps Thermo Fisher In $940M Unit Sales
• Medicines Co. Sues Mylan Over Generic Angiomax
• Genentech Used IP To Form $1B Monopoly, HGS Says
• House Urges FDA To Find Contaminated Heparin Source
• Latham Reps Silverfleet In $675M Sterigenics Sale
• Fed. Circ. Knocks Down $1.7B Humira Patent Verdict
• NY Nets $2.5M In Settlement With Pfizer Subsidiary
• Ex-CEO Stole Trade Secrets, Drug Co. Says
• Roxane Agrees To Delay Launch Of Generic Asacol
• Pfizer Ends Suits Over Nigerian Trovan Deaths
• Philips Reports Possible FCPA Violations
• Sun Pharma Buys Out Remainder Of Caraco
• Spain's Antitrust Watchdog Fines Perfume Group $1.2M
• High Court Won't Review $5B Vioxx Deal
• Ex-Bristol Myers Worker Gets Time Served For IP Theft
• High Court Says Vaccine Act Preempts State Law Claims
• Covington Reps Forest Labs In $1.2B Clinical Data Deal
• Chem Rx Claims Former Exec Lured Clients To Rival
• FCA Liability In A Post-PPACA World
• Dissecting ALI's Restatement Of Torts
• BNLfood Sues Martek Over Access To US Market
• Covidien Faces Class Action Over Off-The-Clock Work
• Zimmer Hits Law Firms With False Advertising Suit
• 11th Circ. Upholds Helvetia Fraudster's Conviction
• Watson's Generic Mucinex Doesn't Infringe, Judge Says
• Biovail Founder Strikes Deal In SEC Fraud Suit
• Abbott Hits Sandoz With New Niaspan Patent Suit
• NZ Bans Avandia Over Cardiovascular Concerns
• Taming The Wild West Of IP Protection
• Sanofi Wins Injunction In Sun IP Suit Over Eloxatin
• Feds Charge 114 In Massive Medicare Fraud Crackdown
• Judge Disses Class Cert. Bid In Sanofi Ketek Suit
• Volcano Ordered To Pay $5M In LightLab Laser Fight
• Senate Bill Aims To Restrict Authorized Generics
• Microsoft, Therasense And Burdens Of Proof
• FDA Issues Recall Of Medtronic Infusion Pumps
• Abbott, Fournier Drop Suit Over Generic TriCor
• Class Action Over Guidant Pacemakers Nixed
• PDL To Pay MedImmune $93M In IP Suit Over Synagis
• La. Seeks $12B In Avandia Medicaid Fraud Suit
• J&J Unit Recalls Antipsychotic Syringes Over Cracks
• Leo Pharma Sues Perrigo Israel Over Generic Taclonex
• Novo Nordisk Faces Criminal Probe Over Diabetes Drugs
• Brothers Plead Guilty To Insider Trading At Sequenom
• Weber Can't Shake Grill False Marking Suit
• Compelling Disgorgement In Antitrust Cases
• Sanofi Bags Genzyme With Incentive-Laden $20B Offer
• Sidley Austin Snags Ex-Inspector General For Chicago
• Quigley To Meet Deadline Or Face Asbestos Claims
• Valeant Must Share In Lilly Defense Costs, Judge Says
• High-Risk Recalls Have Weaker Approval Process: Study
• Inspire Settles AzaSite False Marking Suit
• Q-Med Pays To Shut Down Genzyme Injection IP Fight
• $3.6M Hemispherx Securities Settlement Gets Final OK
• PIC Loses Claim Construction Bid In DNA Patent Suit
• Recalled Triad Products Blamed For Child's Death
• Drug Sales Reps Exempt From OT, 9th Circ. Rules
• Bowman Expands Pharma Practice In New Austin Office
• Obama Takes Aim At Pay-For-Delay In 2012 Budget
• Merck Wins 1st State Fosamax Trial In NJ
• Fed. Circ. Won't Reinstate Lapsed University Patent
• Senate Bill Would Ease Drug Imports, Boost Inspection
• Fed. Circ. Won't Rescue Hako-Med Patent Verdict
• False Marking Suits More Bark Than Bite, Stats Show
• MoFo Snags 2 Attys From Alston, Wilson Sonsini
• Listerine Marketing Actions Consolidated In Fla.
• Pharma/Device Enforcement: A Year In Review
• Looking Back At Employment Litigation In 2010
• AstraZeneca Targets Korean Co. Over Nexium Patents
• Sun Pharma Freezes Generic Eloxatin Sales
• Novartis Says Mylan Infringed Lescol Patent
• Judge Approves Blood Plasma Antitrust MDL
• Calif. Appeals Court Lets J&J Motrin Suit Proceed
• Brazil Orders Shell To Divest Fuel Biz In $12B Venture
• Ex-Greenberg Traurig Atty Appointed CardioNet GC
• Q-Med Board Endorses Galderma's Sweetened Bid
• Squire Sanders Adds Jones Day Life Sciences Atty
• Ex-Paul Hastings Atty Pays To Settle SEC Suit
• Danisco Can't Shake Enzyme Patent Suit
• ArthroCare Strikes Deal To End SEC Accounting Probe
• Retail Reps Hit Crossmark With Overtime Action
• Omnicare V. UnitedHealth And Independent Action
• Sunshine Bill Aims To Restrict Court Secrecy Orders
• Elan Shareholder Suit Gets The Boot
• Lilly Asks High Court To Review Double Patenting
• EU Court Revives Ineos Bid For AlphaRen Mark
• House GOP Calls For Deep FY 2011 Budget Cuts
• Drinker Biddle Picks Up Dechert Dealmaker
• DLA Piper Lures 2 Paul Hastings Litigation Leaders
• King & Spalding Lands 14-Lawyer Filice Brown Team
• J&J, Plaintiffs Seek Arbitration In Sutures MDL
• House Bill Targets Learned Intermediary Defense
• JPML Won't Combine Boehringer Sales Reps' OT Suits
• WilmerHale Snags Silicon Valley IP Pro From Howrey
• Edwards Keeps $74M Award In CoreValve Patent Suit
• Pfizer Appeals Sanctions In Neurontin Antitrust Action
• UMass Gets Unfair Enrichment Claim Nixed In IP Suit
• NC Dental Board Not Immune From Antitrust Law: FTC
• Galderma's $978M Bid Falls Short With Q-Med Investors
• FDA To Fast-Track High-Tech Medical Devices
• Pa. Court Reinstates $10M Verdict In Prempro Suit
• Natco Challenges Gilead Science's Tamiflu Patent
• Judge Orders 2 More Bellwethers In Fosamax MDL
• UCB To Pay PDL $10M Over Antibody Patents
• Lathrop & Gage Targets Biotech With Boston Office
• Square Peg, Round Hole: Product Defects And The FCA
• Attorneys Seek $22M In Fees For Pfizer Settlement
• Ex-GSK Atty Wants Obstruction Charge Nixed
• 9th Circ. Shuts Down Sequus Medical Licensing Spat
• Judge Pushes To Nix 215 Plaintiffs In Neurontin MDL
• Cell Therapeutics Fails To Nix Investor Class Action
• GSK Tightens Avandia Restrictions
• Wachtell Reps Danaher In $6.8B Beckman Coulter Deal
• When To Push For A Determination Under Riegel
• Lobbying Spending Growth Flat For 1st Time In Decade
• AvMed Brings Veteran Atty Ziegler In House
• MDL Panel Won't Consolidate Infested Formula Actions
• Health Net Hits Solvay With AndroGel Antitrust Action
• American, UPS Hit With Data Encryption IP Suits
• States Can Cut Costs Without Medicaid Waivers: HHS
• 3 Staffers Hit Hologic With Overtime Action
• UnitedHealth Wants GSK Paxil Case Back In State Court
• Investors Slam MannKind After FDA Balks On Afrezza
• Lupin Sues Paddock Over Generic Antara
• Case Study: White V. Wyeth
• Somaxon Hits Par With IP Suit Over Silenor Generic
• Metabolite Can't Have Cake, Eat It Too: 10th Circ.
• Law360 Corporate Finance Editorial Advisory Board
• Law360 Intellectual Property Editorial Advisory Board
• Australian Judge Allows Sale Of Generic Taxotere
• US To Join FCA Action Against Abbott Over Depakote
• ITC To Investigate Birthing Dolls From China
• Watson Settles Androderm False Marking Suit
• Avastin Plus Chemo Equals Higher Death Risk: Study
• Actavis Ordered To Pay $170M In Medicaid Fraud Suit
• Genzyme Seeks Toss Of Investors' Insider Trading Suit
• Wyeth Loses Bid To Stay Stent Patent Dispute
• Drug Co. Valeant To Snap Up PharmaSwiss For $484M
• Direct Purchasers' Plavix Antitrust Actions Tossed